BOLD-300 by BTW LABS — Premium Boldenone Undecylenate
Achieve your fitness objectives with BOLD-300, a professional-grade formula designed for stability and efficiency. Whether you are looking for controlled results or a steady regimen, this high-quality product provides the reliability needed for serious athletes.
Specifications
| Active Substance | Boldenone Undecylenate |
| Manufacturer | BTW Labs |
| Formulation | 1 vial x 10ml x 300 mg/ml |
| Classification | Anabolic Steroid |
| Half-Life | 14 days |
| Carrier Oil | Grap eseed Ethyl Oleate |
| Dosage | Men 400-1000 mg/week |
Description
BOLD-300 is formulated with Boldenone Undecylenate, a long-acting ester known for its extended 14-day half-life. This slow-release profile is ideal for users seeking consistent blood concentrations without the drastic peaks and valleys associated with shorter-acting esters. Due to its low aromatization rate, it presents a minimal risk of water retention and estrogen-related side effects, making it an excellent choice for those prioritizing a lean, controlled physique. Its low hepatotoxicity profile further enhances its suitability for long-term, responsible use.
Shipping & Delivery
Please note that temporary shipping restrictions are currently in effect for Switzerland, Japan, Iceland, New Zealand, Singapore, Israel, Taiwan, Malta, Norway, Denmark, Alaska, Hawaii, Puerto Rico, and Guam. Additionally, military addresses (including APO and FPO) are not currently supported. For customers in Hawaii, domestic warehousing is available through our USA facility.
FAQ
What is the risk of water retention?
Water retention is low, making it ideal for maintaining a lean physique.
Is acne a common side effect?
Acne is rarely reported with the use of BOLD-300.
How does the aromatization profile look?
This product features low aromatization, reducing the likelihood of estrogen-related side effects.
Is it hepatotoxic?
The product demonstrates low hepatotoxicity, making it safer for the liver compared to many oral alternatives.
Does it report HBR issues?
No HBR issues are associated with this formulation.